According to a new market research study of “Middle East & Africa (MEA) Pain Management Devices Forecast to 2027 - COVID-19 Impact and Global Analysis by Product and Application, the Middle East & Africa (MEA) pain management devices is projected to reach US$ 235.72 million by 2027 from US$ 140.15 million in 2019. The market is estimated to grow at CAGR of 6.8 % from 2020 to 2027. The report highlights trends prevailing in the Middle East & Africa (MEA) Pain Management Devices market and the factors driving market along with those that act as hindrances.
Based on Product, the Middle East & Africa (MEA) pain management devices market is further segmented into neuromodulation devices, ablation devices, and analgesic infusion pumps. The neuromodulation devices segment held the largest share of the market in 2019. However, the ablation devices segment is estimated to register the highest CAGR in the market during the forecast period. Neuromodulation devices are technically advanced; they are designed to treat migraine attacks and the cluster of headaches. The devices enhance or suppress the nervous system activities that it to reduce pain. A neuromodulation device utilizes electrical currents or magnets to control signaling activity in the brain. A neuromodulation device is often known as a neurostimulator and has two types, such as portable and implantable. The FDA has issued few approvals for the neuromodulation devices to treat migraines. The segment is further divided into transcutaneous electrical nerve stimulation (TENS) devices and spinal cord stimulation (SCS) devices
Middle East & Africa (MEA) pain management devices market is expected to grow owing to factors such as growth include growing Incidences of chronic pain and market player initiatives. Whereas, the market is likely to have negative impact due to the high cost of pain management devices, such as its nearly impossible for the middle class to effort pain management devices.
Pfizer Inc, Abbott, Boston Scientific Corporation, Medtronic, BD, are among the leading companies operating in the Middle East & Africa (MEA) pain management devices market.
The report segments in Middle East & Africa (MEA) Pain Management Devices market as follows:
By Product
By Application
By Country
Reasons to Buy
Based on Product, the Middle East & Africa (MEA) pain management devices market is further segmented into neuromodulation devices, ablation devices, and analgesic infusion pumps. The neuromodulation devices segment held the largest share of the market in 2019. However, the ablation devices segment is estimated to register the highest CAGR in the market during the forecast period. Neuromodulation devices are technically advanced; they are designed to treat migraine attacks and the cluster of headaches. The devices enhance or suppress the nervous system activities that it to reduce pain. A neuromodulation device utilizes electrical currents or magnets to control signaling activity in the brain. A neuromodulation device is often known as a neurostimulator and has two types, such as portable and implantable. The FDA has issued few approvals for the neuromodulation devices to treat migraines. The segment is further divided into transcutaneous electrical nerve stimulation (TENS) devices and spinal cord stimulation (SCS) devices
Middle East & Africa (MEA) pain management devices market is expected to grow owing to factors such as growth include growing Incidences of chronic pain and market player initiatives. Whereas, the market is likely to have negative impact due to the high cost of pain management devices, such as its nearly impossible for the middle class to effort pain management devices.
Pfizer Inc, Abbott, Boston Scientific Corporation, Medtronic, BD, are among the leading companies operating in the Middle East & Africa (MEA) pain management devices market.
The report segments in Middle East & Africa (MEA) Pain Management Devices market as follows:
By Product
- Neuromodulation Devices
- Transcutaneous Electrical Nerve Stimulation (TENS) Devices
- Spinal Cord Stimulation (SCS) Devices
- Ablation Devices
- Radiofrequency Ablation Devices
- Cryoablation Devices
- Analgesic Infusion Pumps
- Intrathecal Infusion Pumps
- External Infusion Pumps
By Application
- Neuropathic Pain
- Cancer Pain
- Facial Pain and Migraine
- Musculoskeletal Pain
- Others
By Country
- Middle East & Africa (MEA)
- Saudi Arabia
- South Africa
- UAE
Reasons to Buy
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the MEA pain management devices market.
- Highlights key business priorities in order to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in the North America pain management devices market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth market trends and outlook coupled with the factors driving the market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.
Table of Contents
1. Introduction
3. Research Methodology
4. MEA Pain Management Devices Market Landscape
5. MEA Pain Management Devices Market Key Market Dynamics
6. Pain Management Devices Market - MEA Analysis
7. Pain Management Devices Market Analysis - by Product Type
8. Pain Management Devices Market Analysis - by Application
9. Pain Management Devices Market - Geographic Analysis
10. Impact of COVID-19 Pandemic on MEA Pain Management Devices Market
11. Company Profiles
12. Appendix
List of Tables
List of Figures
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Pfizer Inc
- Abbott
- Boston Scientific Corporation
- Medtronic
- BD
